Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEND: Difluprednate vs Nepafenac in Uveitic Macular Edema
NCT01939691Phase 4Terminated
- Sponsor
- University of California, San Francisco
- Start
- Sep 2018
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in macular edema comparing Difluprednate, Nepafenac + Prednisolone and Difluprednate + Nepafenac (3 arms). Primary endpoint: Central Subfield Thickness at 4 weeks. Started Sep 2018; status: terminated.
02
Drugs
difluprednatenepafenac
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01939691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939691.